[HTML][HTML] Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials
EA Stewart, AS Lukes, R Venturella, Y Li… - American journal of …, 2023 - Elsevier
Background Symptomatic uterine fibroids are burdensome to live with; they are associated
with symptom-related distress, affect daily activities, and reduce health-related quality of life …
with symptom-related distress, affect daily activities, and reduce health-related quality of life …
Treatment of uterine fibroid symptoms with relugolix combination therapy
A Al-Hendy, AS Lukes, AN Poindexter III… - … England Journal of …, 2021 - Mass Medical Soc
Background Uterine fibroids are a common cause of heavy menstrual bleeding and pain.
Treatment with the combination of relugolix (an oral gonadotropin-releasing hormone …
Treatment with the combination of relugolix (an oral gonadotropin-releasing hormone …
[HTML][HTML] Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study
EA Stewart, A Al-Hendy, AS Lukes… - American journal of …, 2024 - Elsevier
Background In the LIBERTY Long-Term Extension study, once-daily relugolix combination
therapy (40 mg relugolix, estradiol 1 mg, norethindrone acetate 0.5 mg) substantially …
therapy (40 mg relugolix, estradiol 1 mg, norethindrone acetate 0.5 mg) substantially …
Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials
R Venturella, T Rechberger, J Zatik… - Gynecological …, 2023 - Taylor & Francis
Objective In the 24-week, phase 3 LIBERTY 1 (L1) and LIBERTY 2 (L2) trials, relugolix
combination therapy (relugolix-CT (relugolix 40 mg, estradiol 1 mg, norethisterone acetate …
combination therapy (relugolix-CT (relugolix 40 mg, estradiol 1 mg, norethisterone acetate …
[HTML][HTML] LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids
Background In the pivotal LIBERTY 1 and 2 trials and long-term extension study, once-daily
relugolix combination therapy (40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone …
relugolix combination therapy (40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone …
Relugolix/estradiol/norethisterone (norethindrone) acetate: a review in symptomatic uterine fibroids
YY Syed - Drugs, 2022 - Springer
An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as
norethindrone) acetate (Ryeqo®; Myfembree®) has been approved for the management of …
norethindrone) acetate (Ryeqo®; Myfembree®) has been approved for the management of …
LIBERTY randomized withdrawal study: 2-year efficacy and safety of relugolix combination therapy in women with heavy menstrual bleeding associated with uterine …
Objective In the pivotal LIBERTY 1 and 2 trials and Long-Term Extension (LTE) study, once-
daily relugolix combination therapy (Rel-CT: relugolix 40 mg, estradiol 1 mg, norethindrone …
daily relugolix combination therapy (Rel-CT: relugolix 40 mg, estradiol 1 mg, norethindrone …
Treatment of symptoms of uterine fibroids with relugolix combination therapy: Efficacy and safety results from the Phase 3 LIBERTY 1 clinical trial
A Al-Hendy, AS Lukes, A Poindexter, R Venturella… - Fertility and …, 2019 - fertstert.org
Objective To evaluate the efficacy and safety of 24 weeks of treatment with the oral GnRH
receptor antagonist, relugolix, in combination with estradiol (E2) and norethindrone acetate …
receptor antagonist, relugolix, in combination with estradiol (E2) and norethindrone acetate …
LIBERTY: Long-term extension study demonstrating one-year efficacy and safety of relugolix combination therapy in women with symptomatic uterine fibroids
A Al-Hendy, AS Lukes, A Poindexter, R Venturella… - Fertility and …, 2020 - fertstert.org
Objective In the LIBERTY 1 and 2 trials, once-daily relugolix combination therapy (Rel-CT)
reduced menstrual blood loss (MBL) volume and pain in women with uterine fibroids (UF) …
reduced menstrual blood loss (MBL) volume and pain in women with uterine fibroids (UF) …
[HTML][HTML] Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids
A Al-Hendy, L Bradley, CD Owens, H Wang… - American journal of …, 2021 - Elsevier
Background Uterine fibroids are one of the most common neoplasms found among women
globally, with a prevalence of approximately 11 million women in the United States alone …
globally, with a prevalence of approximately 11 million women in the United States alone …